NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

UroGen Pharma Ltd. (URGN) Stock Analysis

UroGen Pharma Ltd. (URGN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

URGN

$44.09

−$0.79 (−1.76%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare URGN with… →

URGN Key Statistics

As of Sep 4, 2026
Trading
Open
$44.54
Previous Close
$44.88
Day's Range
43.50–45.10
52-Week Range
15.86–50.81
Volume
779.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.58
Valuation
Market Cap
$2.16B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
15.78
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
11.42
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.97
Financials (FY)
Revenue (FY)
$109.79M+21.45%
Net Income (FY)
−$153.49M
Profit marginThe share of revenue left as profit after all costs and taxes.
−51.73%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
48.88M
1-Year Return
+134.52%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
816.55K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

URGN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+88.26%
2025+119.91%
2024−29.00%
2023+69.11%
2022−6.73%
2021−47.23%
2020−46.00%
2019−22.50%
2018+15.72%
2017 (partial year)+166.17%

As of September 4, 2026.

URGN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$109.79M−$153.49M−139.8%
2024$90.40M−$126.87M−140.4%
2023$82.71M−$102.24M−123.6%
2022$64.36M−$109.78M−170.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$109.79M$97.34M−$124.86M−$153.49M−139.8%
2024$90.40M$81.52M−$96.78M−$126.87M−140.4%
2023$82.71M$73.35M−$65.54M−$102.24M−123.6%
2022$64.36M$56.70M−$79.04M−$109.78M−170.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

URGN Valuation vs Biotechnology Median

Median of 656 stocks
MetricURGNBiotechnology medianvs median
P/S ratio11.4215.2625% below
Profit margin−51.73%0.00%51.7 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

UroGen Pharma Ltd. (URGN) carries a market capitalisation of $2.16B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 300 employees.

Over the past 52 weeks the price has ranged from $15.86 to $50.81. URGN last closed at $44.09 on September 4, 2026. That is −$0.79 (−1.76%) against the previous close. The latest close sits 177.99% above that 52-week low.

Financial Health

In fiscal 2025, UroGen Pharma Ltd. reported revenue of $109.79M. Against the prior fiscal year total of $90.40M, that is a change of +21.45%. The same year closed with a net loss of $153.49M. Profit margin runs at −51.73%. That is 51.7 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −1.97.

Across the 4 fiscal years on file, revenue moves from $64.36M in 2022 to $109.79M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 15.78. Measured against sales, the shares trade at 11.42 times revenue. On price-to-sales that is 25.19% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 1.58. Annualized volatility over the trailing 9 years is 79.5%. The trailing one-year price return is +134.52%. Measured over 5 years, that is +19.73% a year compounded.

Growth & Income

No dividend is on file for URGN.

Across the complete calendar years on file, 2025 returned +119.91% and 2021 returned −47.23%. Of the 8 complete calendar years on file, 3 finished higher. So far in 2026 the price is +88.26%.

Peer Comparison

UroGen Pharma Ltd. (URGN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
UroGen Pharma Ltd. URGN $2.16B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. UroGen Pharma Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About UroGen Pharma Ltd.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

Visit website →